AI: How does this technological revolution fit with the pharmaceutical regulators who oversee the pharmaceutical sector at ...

Insilico Medicine and Qilu Pharmaceutical Group announced a strategic collaboration to jointly develop small-molecule inhibitors for cardiometabolic diseases, combining Insilico’s generative AI–driven ...

The UK pharmaceutical giant AstraZeneca is doubling down on its commitment to the Chinese drugmaker CSPC Pharmaceutical Group ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Chinese drugmaker Qilu Pharmaceutical will be responsible for developing metabolic disease drug candidates from Insilico Medicine under a contract with a total value that "approaches" $120 million, ...

A large share of medicines developed today may never reach patients for a surprisingly simple reason: they cannot dissolve well enough in water. For most treatments, the oral route remains the gold ...

The Union Health Ministry has amended the NDCT Rules, 2019 to reduce regulatory burden, waive permissions for low-risk ...

SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland)The ...

CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern ...

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (RDW), a leader in space infrastructure for the next-generation space economy, has been awarded a NASA contract to launch four additional ...

Americans spent more than $700 billion on prescription medicines last year. However, many of them remain worried about the safety of their medications.